Icahn claims victory as Biogen tots up tally
This article was originally published in Scrip
Executive Summary
Carl Icahn, the activist investor who owns 5.6% of Biogen Idec, is claiming victory in his proxy battle to have two of his nominees appointed to the biotech's board, according to reports in the media.